文献速递骨显像与常规 SPECT核素与放射性配体治疗肿瘤 PET/CT

223Ra与18F-氟化物显像预测去势抵抗性前列腺癌骨病灶对223Ra-二氯化物治疗反应的可能性

The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-06-13

本研究对5例去势抵抗性前列腺癌患者按体重给予223Ra-二氯化物110 kBq/kg,间隔6周两次静脉注射,通过系列223Ra扫描计算骨转移灶吸收剂量,并评估其与18F-氟化物摄取及治疗反应的关系。结果显示转移灶吸收剂量范围为0.6 Gy至44.1 Gy,患者内最大与最小病灶剂量平均相差5.3倍,病灶吸收剂量与18F-氟化物摄取变化相关(r²=0.52),基线18F-氟化物摄取与治疗12周后摄取变化呈对数线性关系(r²=0.77)。

要点

  • 转移性骨病灶吸收剂量范围为0.6 Gy至44.1 Gy,患者内最大与最小病灶剂量平均相差5.3倍(范围2.5-11.0)。
  • 病灶吸收剂量与系列18F-氟化物摄取变化相关(r²=0.52)。
  • 基线18F-氟化物摄取与治疗12周后摄取变化呈对数线性关系(r²=0.77)。

核心结论

  • 转移性病灶吸收剂量估算存在患者间和患者内异质性。
  • 观察到223Ra病灶吸收剂量与后续病灶反应之间的关系。
  • 对这一小群患者的分析提示,骨转移灶基线18F-氟化物摄取与相应的223Ra摄取、相关223Ra吸收剂量及后续病灶治疗反应显著相关。

研究设计与样本

  • 5例患者接受两次223Ra-二氯化物静脉注射,间隔6周,按全身重量110 kBq/kg给药。
  • 通过系列223Ra扫描确定转移灶中223Ra随时间分布及病灶剂量学。
  • 在第一疗程治疗前(基线)、第6周第二次治疗前及基线后第12周进行18F-氟化物PET/CT显像。

主要发现

  • 转移性骨病灶吸收剂量范围为0.6 Gy至44.1 Gy。
  • 个体患者内最大与最小病灶剂量平均相差5.3倍(范围2.5-11.0)。
  • 病灶吸收剂量与系列18F-氟化物摄取变化相关(r²=0.52)。
  • 基线18F-氟化物摄取与第一疗程后12周摄取变化呈对数线性关系(r²=0.77)。
  • 病灶中223Ra与18F-氟化物摄取相关(r=0.75),223Ra吸收剂量与18F-氟化物摄取相关(r=0.96)。

局限性

  • 分析基于这一小群患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aims of this study were to calculate bone lesion absorbed doses resulting from a weight-based administration of 223Ra-dichloride, to assess the relationship between those doses and corresponding 18F-fluoride uptake and to assess the potential of quantitative 18F-fluoride imaging to predict response to treatment. METHODS: Five patients received two intravenous injections of 223Ra-dichloride, 6 weeks apart, at 110 kBq/kg whole-body weight. The biodistribution of 223Ra in metastatic lesions as a function of time after administration as well as associated lesion dosimetry were determined from serial 223Ra scans. PET/CT imaging using 18F-fluoride was performed prior to the first treatment (baseline), and at week 6 immediately before the second treatment and at week 12 after baseline. RESULTS: Absorbed doses to metastatic bone lesions ranged from 0.6 Gy to 44.1 Gy. For individual patients, there was an average factor difference of 5.3 (range 2.5-11.0) between the maximum and minimum lesion dose. A relationship between lesion-absorbed doses and serial changes in 18F-fluoride uptake was demonstrated (r2 = 0.52). A log-linear relationship was demonstrated (r2 = 0.77) between baseline measurements of 18F-fluoride uptake prior to 223Ra-dichloride therapy and changes in uptake 12 weeks after the first cycle of therapy. Correlations were also observed between both 223Ra and 18F-fluoride uptake in lesions (r = 0.75) as well as between 223Ra absorbed dose and 18F-fluoride uptake (r = 0.96). CONCLUSIONS: There is both inter-patient and intra-patient heterogeneity of absorbed dose estimates to metastatic lesions. A relationship between 223Ra lesion absorbed dose and subsequent lesion response was observed. Analysis of this small group of patients suggests that baseline uptake of 18F-fluoride in bone metastases is significantly correlated with corresponding uptake of 223Ra, the associated 223Ra absorbed dose and subsequent lesion response to treatment.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Murray I, Chittenden SJ, Denis-Bacelar AM, et al. The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017. PMID: 28612079. doi:10.1007/s00259-017-3744-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。